Table 6.
Sensitivity and specificity, confirmed MM cases
| Marker | Sensitivity, MM | Specificity, against carcinoma | ||||
|---|---|---|---|---|---|---|
| Positive MM markers | positive IR, number | positive IR, % | literature data, % | negative IR, number % | negative IR, % | literature data, % |
| Calretinin, nucleus | 49/49 | 100 | 821 96.42 |
5/5 | 100 | 851;2 |
| EMA, cell membrane | 43/49 | 87.8 | 843 | 3/5 | 60 | 563 |
| Podoplanin, cell membrane | 44/46 | 95.6 | 864 | 2/3 | 66.7 | 1004 |
| Mesothelin, cell membrane | 44/48 | 91.7 | 1005 | 4/4 | 100 | 615 |
| Thrombomodulin, cell membrane | 7/7 | 100 | 611 | 2/5 | 40 | 801 |
| HBME-1, cell membrane or cytoplasm | (4+2)/8 | 75 | 851 | (2-1)/5 | 20 | 431 |
| CK5/6 | 3/3 | 100 | 831 | 3/5 | 60 | 851 |
| Negative MM markers | negative IR, number | negative IR, % | positive IR, number | positive IR, % | ||
| CEA, monoclonal | 49/49 | 100 | 811 | 1/5 | 20 | 971 |
| Ber-Ep4 | 40/49 | 81.6 | 801 | 3/5 | 60 | 901 |
| CD15 | 7/7 | 100 | 84.96 | 1/5 | 20 | 816 |
| Sialosyl-TN | 6/7 | 85.7 | 76.56 | 1/5 | 20 | 816 |
| TTF-1 | 3/3 | 100 | 721 | 5/5 | 100 | 1001 |
Specificity, own results: against AC and pulmonary pleomorphic carcinoma.
Comparison to some selected data from literature.
1 King et al. 2006, meta-analysis of literature data, MM with epithelioid areas against pulmonary AC [27].
2 Takeshima et al. 2009: sensitivity epithelial/mixed MM 96.4%/90% [1]. Yaziji et al. 2006: sensitivity 95%, specificity against AC 87%, both with 10% positive cutoff [28].
1, 2 Calretinin IR not specified.
3 Wick et al. 1990, related to epithelial MM and pulmonary AC [29].
4 Ordóñez 2005, related to epithelial MM and AC [21].
5 Ordóñez 2003a, related to epithelial MM and pulmonary AC [30].
6 Brockstedt et al. 2000, related to epithelial/mixed MM and AC [31].